Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medicines, with its operations spanning Taiwan and the United States. Its core mission involves developing biosimilars aimed at treating severe conditions like neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's robust product portfolio includes TX01 and TX-05, both of which have successfully completed Phase III clinical trials. Additionally, TX-04 and TX-16 are currently undergoing Phase I clinical trials, while TX-52 and other potential therapies are in the pre-clinical development stage.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Target Price
The average target price of 6541.TW is 153 and suggests 274% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc